AFYX Therapeutics

About

AFYX Therapeutics is a clinical stage biopharmaceutical company

Copenhagen,Hovedstaden,Denmark
11 - 50

Highlights

Details

Last Funding Type: Series A
Last Funding Money Raised: €16.20M
Industries: Biotechnology,Clinical Trials,Delivery,Health Care,Pharmaceutical,Therapeutics
Founded date: Jan 1, 2013
Number Of Employee: 11 - 50
Operating Status: Active
Also Known As: Dermtreat ApS

AFYX Therapeutics is changing the way mucosal diseases are treated. They are a topical drug delivery company developing a pipeline of targeted treatments for conditions that currently lack approved therapy options. Their proprietary Rivelin® patch is flexible, biodegradable, and adhesive to mucosal surfaces. Designed with electrospinning technology, it delivers a therapeutic directly to the site in need, without interfering with patients’ daily activities.

Funding Rounds

Number of Funding Rounds

Total Funding Amount

3

€16.27M $13M

AFYX Therapeutics has raised a total of €16.27M $13M in funding over 2 rounds. Their latest funding was raised on Jun 24, 2019 from a Debt Financing round.

Announced Date	Round	Money Raised	Number of Investors	Lead Investors	Post Valuation
Jun 24, 2019	Debt Financing	$13M	2	—	—	Detail
Jan 1, 2019	Grant	€71.42K	1	—	—	Detail
May 9, 2017	Series A	€16.20M	3	Lundbeckfonden Emerge Novo Holdings Sofinnova Investments	—	Detail